Innoviva (INVA) Change in Accured Expenses (2010 - 2026)
Innoviva posted quarterly Change in Accured Expenses of -$9.8 million for Q1 2026, down 103.72% year-on-year from $263.2 million in Q1 2025, and down 207.02% on a QoQ basis from -$3.2 million in Q3 2025.
Innoviva (INVA) has 17 years of Change in Accured Expenses data on file, last reported at -$9.8 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 103.72% year-over-year to -$9.8 million; the trailing twelve-month figure through Mar 2026 stood at -$11.1 million (down 49.45% YoY), and the FY2025 full-year result was -$1.8 million, down 159.26% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$9.8 million, down from -$3.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $6.7 million in Q2 2025 and bottomed at -$9.8 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is -$1.1 million (2023), against an average of -$818538.5.
- The widest annual swing landed in 2022, when Change in Accured Expenses jumped 832.16%; it then slumped 358.23% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at -$1.9 million in 2022, then surged by 44.34% to -$1.1 million in 2023, then tumbled by 141.51% to -$2.6 million in 2024, then decreased by 23.25% to -$3.2 million in 2025, then tumbled by 207.02% to -$9.8 million in 2026.
- The last three Change in Accured Expenses figures came in at -$9.8 million (Q1 2026), -$3.2 million (Q3 2025), and $6.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | -9.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.80 Mn |
| Mar 31, 2026 | -9.80 Mn |
| Sep 30, 2025 | -3.19 Mn |
| Sep 30, 2025 | -3.19 Mn |
| Jun 30, 2025 | 6.74 Mn |
| Jun 30, 2025 | 6.74 Mn |
| Mar 31, 2025 | -4.81 Mn |
| Mar 31, 2025 | -4.81 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Jun 30, 2024 | 2.59 Mn |
| Jun 30, 2024 | 2.59 Mn |
| Mar 31, 2024 | -2.59 Mn |
| Mar 31, 2024 | -2.59 Mn |
| Sep 30, 2023 | -1.07 Mn |
| Sep 30, 2023 | -1.07 Mn |
| Jun 30, 2023 | -372,000.00 |
| Jun 30, 2023 | -372,000.00 |
| Mar 31, 2023 | -565,000.00 |
| Mar 31, 2023 | -565,000.00 |
| Sep 30, 2022 | -1.93 Mn |
| Sep 30, 2022 | -1.93 Mn |
| Jun 30, 2022 | 4.82 Mn |
| Jun 30, 2022 | 4.82 Mn |
| Mar 31, 2022 | 2.12 Mn |
| Mar 31, 2022 | 2.12 Mn |
| Sep 30, 2021 | -533,000.00 |
| Sep 30, 2021 | -533,000.00 |
| Jun 30, 2021 | -936,000.00 |
| Jun 30, 2021 | -936,000.00 |
| Mar 31, 2021 | 227,000.00 |
| Mar 31, 2021 | 227,000.00 |
| Dec 31, 2020 | 3.29 Mn |
| Dec 31, 2020 | 3.29 Mn |
| Sep 30, 2020 | -2.47 Mn |
| Sep 30, 2020 | -2.47 Mn |
| Jun 30, 2020 | 2.47 Mn |
| Jun 30, 2020 | 2.47 Mn |
| Mar 31, 2020 | -2.48 Mn |
| Mar 31, 2020 | -2.48 Mn |
| Dec 31, 2019 | 2.38 Mn |
| Dec 31, 2019 | 2.38 Mn |
| Sep 30, 2019 | -2.49 Mn |
| Sep 30, 2019 | -2.49 Mn |
| Jun 30, 2019 | -168,000.00 |
| Jun 30, 2019 | -168,000.00 |
| Mar 31, 2019 | 166,000.00 |
| Mar 31, 2019 | 166,000.00 |
| Dec 31, 2018 | -961,000.00 |
| Dec 31, 2018 | -961,000.00 |
| Sep 30, 2018 | 844,000.00 |
| Sep 30, 2018 | 844,000.00 |
| Jun 30, 2018 | 163,000.00 |
| Jun 30, 2018 | 163,000.00 |
| Mar 31, 2018 | -1.70 Mn |
| Mar 31, 2018 | -1.70 Mn |
| Dec 31, 2017 | 4.18 Mn |
| Dec 31, 2017 | 4.18 Mn |
| Sep 30, 2017 | -4.50 Mn |
| Sep 30, 2017 | -4.50 Mn |
| Jun 30, 2017 | 1.67 Mn |
| Jun 30, 2017 | 1.67 Mn |
| Mar 31, 2017 | -1.43 Mn |
| Mar 31, 2017 | -1.43 Mn |
| Dec 31, 2016 | 1.58 Mn |
| Dec 31, 2016 | 1.58 Mn |
| Sep 30, 2016 | -678,000.00 |
| Sep 30, 2016 | -678,000.00 |
| Jun 30, 2016 | -2,000.00 |
| Jun 30, 2016 | -2,000.00 |
| Mar 31, 2016 | -625,000.00 |
| Mar 31, 2016 | -625,000.00 |
| Dec 31, 2015 | 126,000.00 |
| Dec 31, 2015 | 126,000.00 |
| Sep 30, 2015 | 858,000.00 |
| Sep 30, 2015 | 858,000.00 |
| Jun 30, 2015 | -193,000.00 |
| Jun 30, 2015 | -193,000.00 |
| Mar 31, 2015 | -1.52 Mn |
| Mar 31, 2015 | -1.52 Mn |
| Dec 31, 2014 | 4.68 Mn |
| Dec 31, 2014 | 4.68 Mn |
| Sep 30, 2014 | -8.14 Mn |
| Sep 30, 2014 | -8.14 Mn |
| Jun 30, 2014 | 3.77 Mn |
| Jun 30, 2014 | 3.77 Mn |
| Mar 31, 2014 | 4.45 Mn |
| Mar 31, 2014 | 4.45 Mn |
| Dec 31, 2013 | 1.38 Mn |
| Dec 31, 2013 | 1.38 Mn |
| Sep 30, 2013 | 1.53 Mn |
| Sep 30, 2013 | 1.53 Mn |
| Jun 30, 2013 | 6.12 Mn |
| Jun 30, 2013 | 6.12 Mn |
| Mar 31, 2013 | -3.18 Mn |
| Mar 31, 2013 | -3.18 Mn |
| Dec 31, 2012 | 2.07 Mn |
| Dec 31, 2012 | 2.07 Mn |
| Sep 30, 2012 | 2.05 Mn |
| Sep 30, 2012 | 2.05 Mn |
| Jun 30, 2012 | -593,000.00 |
| Jun 30, 2012 | -593,000.00 |
| Mar 31, 2012 | -5.36 Mn |
| Mar 31, 2012 | -5.36 Mn |
| Dec 31, 2011 | 5.80 Mn |
| Dec 31, 2011 | 5.80 Mn |
| Sep 30, 2011 | 2.81 Mn |
| Sep 30, 2011 | 2.81 Mn |
| Jun 30, 2011 | 2.54 Mn |
| Jun 30, 2011 | 2.54 Mn |
| Mar 31, 2011 | -6.03 Mn |
| Mar 31, 2011 | -6.03 Mn |
| Dec 31, 2010 | 4.91 Mn |
| Dec 31, 2010 | 4.91 Mn |
| Sep 30, 2010 | -1.20 Mn |
| Sep 30, 2010 | -1.20 Mn |